1st Quarter - Amendment

WALGREEN COMPANY for WALGREEN COMPANY

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$570,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Amendment (this page) Apr 21, 2015 $570,000 Replaced
1st Quarter - Report Apr 21, 2015 $570,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R. 1021 - the "Protecting the Integrity of Medicare Act," all provisions related to fraud, waste and abuse initiatives in Medicare for pharmacies and beneficiaries. S. 776 - the "Medication Therapy Management Empowerment Act of 2015," all provisions related to expanding access to Medicare Part D Medication Therapy Management (MTM) for beneficiaries with a single chronic illness of cardiovascular disease, COPD, hyperlipidemia or diabetes. Issues related to Medicaid reimbursement; no legislation.

LobbyistCovered position, as disclosed
KATHARINE TROLLER BOND New 2013-2015 Legislative Dir, Rep Greg Walden; 2011-2013 Legislative Dir, Rep Rich Nugent & House Rules (shared staff); 2009-2011 Legislative Asst, Rep Ginny Brown-Waite; 2008-2009 Legislative Correspondent, Rep Ginny Brown-Waite
DEBBIE GARZA —
ALETHIA JACKSON —
EDWARD KALETA —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: H.R. 1021 (114th), S. 776 (114th)

Pharmacy PHA

S. 314 and H.R. 592 - the "Pharmacy and Medically Underserved Areas Enhancement Act," all provisions related to amending the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved communities, consistent with state scope of practice laws. Issues related to track and trace of pharmaceuticals in the Drug Quality and Security Act (DQSA); no legislation.

LobbyistCovered position, as disclosed
KATHARINE TROLLER BOND New 2013-2015 Legislative Dir, Rep Greg Walden; 2011-2013 Legislative Dir, Rep Rich Nugent & House Rules (shared staff); 2009-2011 Legislative Asst, Rep Ginny Brown-Waite; 2008-2009 Legislative Correspondent, Rep Ginny Brown-Waite
DEBBIE GARZA —
ALETHIA JACKSON —
EDWARD KALETA —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: S. 314 (114th), H.R. 592 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.